Citations

Clear

249 citation(s) found for "St-Denis, L".

Distinct senescent β-cell senotypes differentially drive islet aging and dysfunction
Pan, Hui , Dreyfuss, Jonathan M. , Jackson, Maya, Domanskyi, Sergii , Baker, Dylan, Carapeto, Priscila , Cahill, Christopher, Le, Sandra, Hela, Francesko , Eryilmaz, Giray Naim , Wu, Fan, Yu, Bofei, Espinoza, Sara , Pena, Alejandro , Cigarroa, Francisco , Abrahamian, Gregory , Woodworth, Jillian L., Adams, Peter D., Kirkland, James L, Musi, Nicolas , Espinoza, Sara , Iwasaki, Kanako , Pan, Hui , Dreyfuss, Jonathan , Jackson, Maya , Domanskyi, Sergii , Carapeto, Priscila , Hela, Francesko , Alcoforado Diniz, Juliana , Wu, Pei-Hsun , Yu, Bofei , Wirtz, Denis , Espinoza, Sara , Pena, Alejandro , Cigarroa, Francisco G , Abrahamian, Gregory , Adams, Peter , Ucar, Duygu , Chuang, Jeffrey H , Garovic, Vesna D , Tchkonia, T , Musi, Nicholas , Kuchel, George A , Robson, Paul , Aguayo-Mazzucato, Cristina , Iwasaki, Kanako , Garovic, Vesna D. , Kirkland, James L. , Tchkonia, Tamar , Kuchel, George A. , Robson, Paul , Aguayo‐Mazzucato, Cristina

Mayo Clinic

No container title available | May 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.25.727705 | PMID 42244625 Get It

ABSTRACT Biological aging greatly impacts the body’s ability to handle glucose, and represents a major risk factor the development and progression of type 2 diabetes (T2D). Nonetheless, despite advances in cellular senescence research and the development of new senolytic therapies, the heterogeneity of cellular senescence in the human endocrine pancreas, as well as its roles in normal aging, remains to be elucidated at the single-cell level. Here, we performed single-cell–resolved spatial proteomics and transcriptomics on intact pancreas from 26 donors (ages 20–80) and multiplexed single-cell RNA sequencing and functional assays on dispersed islets from 14 donors (ages 34–69). We identify two discrete SnC subpopulations distinguished by relative expression of CDKN1A and CDKN2A. CDKN1A ⁺ senescent cells (SnCs) exhibit loss of β-cell identity, impaired insulin secretion, and a proinflammatory SASP associated with increased islet immune infiltration. In contrast, CDKN2A ⁺ SnCs retain transcriptional identity and functional competence, with lower inflammatory signaling. Together, these findings identify heterogeneous and functionally divergent senotypes in the human pancreas, distinguishing an adaptive ( CDKN2A ⁺) from a maladaptive ( CDKN1A ⁺) senescence program, thus providing a mechanism-guided framework for senescence-targeted therapies in T2D.
Real-world clinical outcomes by HER2 expression in locally advanced/metastatic urothelial carcinoma (la/mUC): Results from the global SGNDV-003 retrospective study.
Koshkin, Vadim S. , Jaillon, Christine Abraham, Mar, Nataliya, Maillet, Denis, Shariat, Shahrokh F., Singh, Parminder, Drakaki, Alexandra, Graham, Laura, Merseburger, Axel S. , Huang, Jiaoti, Galsky, Matthew D., Sokolowski, Kevin M. , Jiang, Dingfeng, Lonning, Shaparak, Yu, Hong, Burgess, Earle F., Mar, Nataliya , Maillet, Denis , Shariat, Shahrokh F. , Singh, Parminder Pal , Khaki, Ali Raza , Drakaki, Alexandra , Galsky, Matthew D. , Yin, Lei , Zhang, Wei , Burgess, Earle F.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 4562-4562

10.1200/jco.2026.44.16_suppl.4562 Get It

4562 Background: Approximately 50-80% of patients (pts) with la/mUC have tumors with HER2 protein expression. As HER2-directed therapies enter development, a robust understanding of HER2 prevalence and real-world outcomes with standard-of-care (SOC) therapies across HER2 expression subgroups is needed. SGNDV-003 (NCT05902494) is a global retrospective chart review study in which HER2 status was assessed via central lab testing and outcomes were analyzed by HER2 status in pts with la/mUC. Methods: SGNDV-003, conducted 6/2023-7/2025, included pts with la/mUC who received ≥1 prior treatment (tx) (incl. 1 line of platinum-based chemotherapy [chemo]). HER2 status was centrally tested using a UC-specific investigational immunohistochemistry [IHC] and in situ hybridization (ISH) assays. HER2 status was defined as: HER2-positive (IHC3+ or IHC2+/ISH+), HER2-low (IHC2+/ISH- or IHC1+), HER2-expressing (IHC3+, 2+, 1+), and HER2-zero (IHC0). Index line of therapy (LOT) was defined as the first LOT received after platinum-based chemo. Outcomes included real-world objective response rate (rwORR) (per RECIST 1.1 or physician-assessed response) to index LOT, real-world progression-free survival (rwPFS), and overall survival (OS) from start of index LOT. Data was analyzed via descriptive statistics. Results: A total of 353 pts with la/mUC and available HER2 status were analyzed (male, 76%; median age, 70 years). 70% of pts were HER2 expressing (19% HER2-positive, 51% HER2-low); 30% were HER2-zero. Disease characteristics were well balanced by HER2 status. Index LOT tx and real-world outcomes are shown in the Table. Immuno-oncology therapies (IO) and enfortumab vedotin (EV) were the most common index LOTs. For IO, rwORRs were 21% for HER2-expressing and 17% for HER2-zero. For EV mono, rwORRs were 36% (HER2-expressing) and 38% (HER2-zero), respectively. Conclusions: This global study provides a robust estimate of HER2 distribution in la/mUC based on standardized central lab testing, showing high prevalence of HER2 expression. Real-world outcomes with current SOC therapies were broadly consistent across HER2 subgroups, establishing an important benchmark for the clinical development of HER2-directed therapies in this setting. HER2-positive (n=67) HER2-low (n=181) HER2-expressing (n=248) HER2-zero (n=105) Total (n=353) Real-world Outcomes rwORR, n (%)[95% CI] 17 (25.4)[15.5, 37.5] 50 (27.6)[21.3, 34.7] 67 (27.0)[21.6, 33.0] 22 (21.0)[13.6, 30.0] 89 (25.2)[20.8, 30.1] Median rwPFS (95% CI), mo 2.8(2.0, 4.1) 3.7(2.7, 5.1) 3.0(2.7, 4.5) 2.6(2.1, 3.4) 2.9 (2.6, 3.5) Median OS(95% CI), mo 12.2(9.3, 16.5) 11.5(9.5, 13.5) 11.9(10.3, 13.4) 7.7(5.9, 9.9) 10.8(9.1, 12.3) Index LOT, n% IO EV monoChemoOther tx 37 (55)17 (25)10 (15)3 (5) 94 (52)51 (28)24 (13)14 (8) 131 (53)68 (27)34 (14)17 (7) 65 (62)21 (20)12 (11)7 (7) 196 (56)89 (25)46 (13)24 (7)
Resolving inflammatory bowel disease risk variants to genes and cell types
Zhang, Rui, Gettler, Kyle , Haritunians, Talin , Cleynen, Isabelle , Stevens, Christine R , Zhang, Qian , Tastad, Christopher, Medici, Catalina, Abreu, María T. , Achkar, Jean-Paul, Ahmad, Tariq, Bernstein, Charles, Brooks, Johanne , Bujanda, Luis, Butterworth, Jeffrey, Clark, Katie, Cummings, F, Buono, Joanne Del, Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Jarvis, Mark , Johnston, EL, Kemp, Cheryl, Kennedy, Nick, Lewis, James D. , Li, Andy, Louis, Édouard , Moayyedi, Paul, Moran, G , Newman, Bill, Oglesby, Arabis, Pekow, Joel, Perez, Kate J., Pollok, R, Radford-Smith, Graham , Raffals, L, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Reinisch, Walter , Satsangi, Jack, Selinger, Christian, Shedwell, Sophy, Silverberg, Mark S. , Singh, Salil, Steel, Alan, Uhlig, Holm H. , Verma, Ajay, Weersma, Rinse K. , Xavier, Ramnik, Parkes, M, Lee, James C. , McGovern, D, Anderson, Carl A. , Lee, James , Raine, Tim , Zhang, Rui , Haritunians, Talin , Raine, Tim , Anderson, Carl A , Fachal, Laura , Cleynen, Isabelle , Stevens, Christine R. , Zhang, Qian , Tastad, Christopher , Do, Ron , Achkar, Jean–Paul , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , D’Amato, Mauro , Duerr, Richard H , Ellinghaus, David , Franchimont, Denis , Franke, André , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Julià, Antonio , Kennedy, Nicholas Alexander , Kupcinskas, Juozas , Latiano, Anna , Lewis, James D , McLaughlin, John , Moayyedi, Paul , Mowat, Craig , Newberry, Rodney D. , Perez, Kate J, Prescott, Natalie , Radford‐Smith, Graham L , Raffals, Laura E. , Reinisch, Walter , Rogler, Gerhard , Sands, Bruce E , Satsangi, Jack, Scharl, Michael , Schreiber, Stefan , Sebastian, Shaji , Selinger, Christian P. , Steed, Helen , Vermeire, Séverine , Halfvarson, Jonas , Daly, Mark J. , Lamb, Christopher A , Huang, Hailiang , McGovern, Dermot P.B. , Rioux, John D. , Cho, Judy H , Zhang, Rui

Mayo Clinic

No container title available | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.13.26352926 Get It

Abstract Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
Exome sequencing directly implicates 68 genes in inflammatory bowel disease
Zhu, Ruifei , Zhang, Qian , Yuan, Kai , Zhang, Rui , Turvey, Alexandra K. , Stevens, Christine R , Ahmad, Tariq, Bernstein, Çharles N. , Bokemeyer, Bernd , Brooks, Johanne , Butterworth, Jeffrey, Clark, Katie, Cummings, F, Ennis, Sarah, Färkkilä, M, Faubion, William A. , Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Irving, Peter, Jarvis, Mark , Johnston, EL, Karlson, Elizabeth W, Kemp, Cheryl, Kennedy, Nick, Lees, Charlie, Lewis, James D. , Li, Andy, Louis, Édouard , McGovern, Dermot P.B., Oglesby, Arabis, Perez, Kate J, Pollok, R, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Sands, Bruce, Satsangi, Jack, Schreiber, Stefan, Selinger, Christian, Shedwell, Sophy, Silverberg, M, Singh, Salil, Steel, Alan, Uhlig, H, Verma, Ajay, Vermeire, Séverine , Weersma, Rinse K. , Xavier, Ramnik, Parkes, Miles, Rioux, John D. , Anderson, Carl A. , Raine, Tim , Uhlig, Holm H. , Fachal, Laura , Bernstein, Charles Noah , Bokemeyer, Bernd , Brant, Steven R , Cho, Judy H , Duerr, Richard H , Faubion, William , Franchimont, Denis , Franke, André , Kupcinskas, Juozas , Lamb, Christopher A , Lewis, James D , Loescher, Britt-Sabina , Louis, Edouard , McCauley, Jacob L , Moayyedi, Paul , Newberry, Rodney D , Palotie, Aarno V. , Pekow, Joel , Prescott, Natalie , Sabic, Ksenija , Sands, Bruce E , Silverberg, Mark S , Sokol, Harry , Vermeire, Séverine , Weersma, Rinse K , Xavier, Ramnik J , Yu, Mingrui , Rioux, John D , Daly, Mark J. , Huang, Hailiang , Anderson, Carl A , Raine, Tim , Zhang, Qian , Yuan, Kai , Stevens, Christine R. , Fachal, Laura , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , Ennis, Sarah A. , Färkkilâ, Martti , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Karlson, Elizabeth W. , Kennedy, Nicholas Alexander , Lees, Charlie W. , McCauley, Jacob L. , McGovern, Dermot P.B. , McLaughlin, John , Moayyedi, Paul , Moran, G , Newberry, Rodney D. , Pekow, Joel , Satsangi, Jack, Sazonovs, Aleksejs , Schreiber, Stefan , Selinger, Christian P. , Steed, Helen , Parkes, Miles , Zhang, Rui

Mayo Clinic

No container title available | May 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.08.26352648 | PMID 42180385 Get It

Abstract Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder of the gastrointestinal tract whose genetic basis is only partly resolved because most risk variants identified by genome-wide association studies (GWAS) lie in non-coding regions, limiting direct gene assignment and biological interpretation 1,2 . Here we analysed whole-exome and whole-genome sequencing data from 86,213 IBD cases and 478,363 controls of European ancestry. We identified 68 IBD genes directly implicated by conditionally independent protein-coding associations across the allele frequency spectrum. Many newly implicated IBD genes are supported by orthogonal genomic or pleiotropic evidence, pointing to disease-related pathways and nominating targets with therapeutic relevance. We further identified allelic series and non-additive effects at key loci such as NOD2 and TYK2. These results show that large-scale sequencing can resolve disease genes and pathways that remain ambiguous from non-coding association alone, providing a more direct route from human genetics to biological insight and therapeutic hypotheses.
DELAYED READINGS OF PATCH TEST REACTIONS TO TOPICAL CORTICOSTEROIDS: LOW YIELD
Davis, Mark Denis P., Richardson, Donna M., Farmer, Sara A., Davis, Mark D.P.

Mayo Clinic

Dermatitis® | March 2, 2026 | Volume: 16 | Issue: 2 | Pages: 102-102

10.2310/derm.1.2005.2088 Get It

CONTACT SENSITIVITIES IN ORAL DISEASE
Torgerson, Rochelle R. , Davis, Mark Denis P., Bruce, Alison J., Farmer, Sara A., Rogers, Roy S., Davis, Mark D.P. , Rogers, Roy S.

Mayo Clinic

Dermatitis® | March 2, 2026 | Volume: 16 | Issue: 2 | Pages: 100-100

10.2310/derm.1.2005.2083 Get It

Venous Abnormalities in Biopsy-confirmed Lipodermatosclerosis
Garimella, Vishal, Mukosera, George Tinotenda, Liedl, David , Todd, A., Davis, Mark D.P. , Rooke, Thom W., Alavi, A., Liedl, David A, Davis, Mark Denis P., Garimella, Vishal, Mukosera, George T. , Rooke, Thom W.

Mayo Clinic

Advances in Skin & Wound Care | February 6, 2026 | Volume: 39 | Issue: 3 | Pages: 141-144

10.1097/asw.0000000000000421 | PMID 41649308 Get It

BACKGROUND: Lipodermatosclerosis (LDS) is a type of sclerosing panniculitis that predominantly involves the lower extremities and is characterized by erythema, hemosiderin pigmentation, and sclerotic skin lesions. LDS is a common reason for specialty consultations across clinical settings, including dermatology, vascular medicine, and occasionally the emergency department or internal medicine services. METHODS: To further evaluate the prevalence of venous hypertension in patients with LDS at the authors’ institution, they retrospectively reviewed the findings of lower extremity Doppler ultrasonography with or without segmental pressure (ie, venous ultrasonography) performed for adult patients with biopsy-confirmed LDS who were treated at the Clinic from January 1, 2000, through September 30, 2022. RESULTS: A total of 430 patients were included in the study. Venous ultrasonography findings were abnormal for 327 (76.0%) patients, whereas the other 103 (23.9%) patients had normal findings. Venous hemodynamics studies, including air plethysmography and continuous-wave Doppler ultrasonography, were performed for 33 patients with normal venous ultrasonography findings. Of these patients, 7 had mild valvular incompetence, 12 had abnormal calf muscle pump function, and 2 had pulsatility (backflow in the peripheral vein with elevated right atrial pressure) evident on continuous-wave Doppler ultrasonography. CONCLUSIONS: Overall, the findings extend previous observations that venous abnormalities are commonly present in patients with LDS and may contribute to its pathogenesis. However, a few patients with LDS have normal venous hemodynamics, which suggests that other factors also contribute to LDS pathogenesis.
A phase 1 first-in-human, dose-escalation and -expansion study of RYZ401, a novel radiopharmaceutical therapy (RPT) labeled with actinium-225 ( 225 Ac), in patients with neuroendocrine tumors (NETs) and ot
WONG, R, Anthony, Lowell , Kaván, Petr, Ramirez, R, Allen-Auerbach, Martin S, Prasad, Vikas , Osman, Medhat, Starr, Jason S., Patel, Dipen Chandrakant, Ferreira, Denis Vasconcelos, Susnow, Roberta, Wang, Xuemei, Soares, Heloisa P. , Ramirez, Robert A., Reilley, Matthew J. , Osman, Medhat, Sonbol, Mohamad Bassam , Hálfdánarson, Þorvarður R. , Starr, Jason S. , Singh, Simron

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: No page available

10.1200/jco.2026.44.2_suppl.tps646 Get It

TPS646 Background: SSTR-targeted RPT has transformed the treatment landscape for NETs, significantly improving clinical outcomes in phase 3 studies versus other targeted therapies. Nevertheless, disease progression and renal toxicity after treatment highlight the need for further improvement. Use of the α-emitter 225 Ac as the radioactive component has shown promising results in clinical studies: initial data from ACTION-1 suggest promising efficacy for RYZ101, a first-in-class, highly potent α-emitting RPT, in patients with SSTR+ GEP-NETs progressing after 2–4 cycles of 177 Lu-somatostatin analogs. RYZ401 is a cyclic 6-amino acid SSTR-targeting peptide agonist conjugated to a DOTA chelator bound to 225 Ac. Preclinical data have shown an improved therapeutic window versus DOTATATE. RYZ401 has the potential to deliver higher radiation doses to tumors, with improved renal clearance and lower kidney absorbed dose, potentially eliminating the need for amino acid infusion. Methods: RYZ401-101 is a global, multicenter, phase 1, first-in-human, dose-escalation/-expansion study designed to determine the recommended phase 2 dose (RP2D) and optimal treatment regimen, safety and tolerability, and preliminary efficacy of RYZ401 in patients with NETs and other selected solid tumors expressing SSTRs. Key eligibility criteria: histologically confirmed metastatic or unresectable well-differentiated NETs; WHO grade 1–3 (Ki-67 ≤55%); ≥1 SSTR PET-positive measurable lesion; and disease progression after ≥1 prior treatment line. In dose escalation, 6–18 patients will receive escalating doses of RYZ401 (2.0–11.1 MBq IV Q6W × 2–4 cycles); no amino acid co-infusion is planned. In dose expansion, approximately 80 patients will receive RYZ401 at the RP2D, 40 patients with well-differentiated GEP-NETs (cohort A) and 40 with other SSTR+ tumors including non-GEP-NETs (cohort B). Primary endpoints: dose-limiting toxicities in weeks 1–4 of treatment (dose escalation) and safety (dose expansion). Secondary endpoints: safety, pharmacokinetics, and efficacy outcomes (dose escalation and expansion). RYZ401 dosimetry will be evaluated in a sub-study of 10−16 patients. Enrollment is ongoing in the USA. Clinical trial information: NCT07165132 .
Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias
Badar, Talha , Marando, Ludovica , Latorre-Crespo, Eric, Oliva, Francyess Denis, Lin, Chenyu , McCormick, Benjamin J. , Kettani, Mobachir El , Shah, Kashish, Kusne, Yael , Jamy, Omer , Diebold, Kendall , Coltoff, Alexander , Finke, Christy M. , Foran, James M. , Kharfan‐Dabaja, Mohamed A. , Fan, Yao‐Shan, Jiang, Liuyan , He, Rong , Thomas, M. , Patel, Anand , Viswanatha, D., Shah, Maleeha, Mangaonkar, Abhishek A. , Kirschner, Kristina , Al‐Kali, Aref , Gangat, Naseema, Litzow, Mark R. , Patnaik, Mrinal M. , Latorre‐Crespo, Eric , Latorre, Eric , Lin, Chenyu , El Kettani, Mobachir , Kusne, Yael N , Jamy, Omer , Kharfan-Dabaja, Mohamed A , He, Rong , Patel, Anand , Viswanatha, David, Shah, Mithun V , Saliba, Antoine N , Kirschner, Kristina , Al-Kali, Aref , Gangat, Naseema , Litzow, Mark R. , Patnaik, Mrinal , Badar, Talha , Lasho, Terra L. , Thomas, Miles, Saliba, Antoine N. , Gangat, Naseema

Mayo Clinic

Blood Advances | January 7, 2026 | Volume: 10 | Issue: 5 | Pages: 1746-1755

10.1182/bloodadvances.2025018031 | PMID 41499760 Get It

Abstract TP53 and PPM1D are key regulators of DNA damage response and repair, and somatic mutations in these genes often co-occur in hematopoietic cells, expanding under genotoxic stress. Unlike TP53 mutations, where mechanisms of progression are defined, pathways underlying clonal fitness and transformation in PPM1D mutant cells remain unclear. In collaboration with 5 academic institutions, we analyzed the clinical and molecular landscape of 337 patients with clonal hematopoiesis (CH) and clonal cytopenia of undetermined significance (CCUS) across 4 genotypes: PPM1Dmt/TP53wt (n = 170 [50%]), PPM1Dmt/TP53mt (n = 25 [7%]), TP53mt/PPM1Dwt (n = 17 [5%]), and TP53wt/PPM1Dwt (n = 125 [38%]). All PPM1D variants were truncating, located in exon 6 of the gene, with a median variant allele frequency (VAF) of 6% (range, 0.3%-64%). The PPM1Dmt/TP53mt genotype was most frequently encountered in therapy-related CH/CCUS (t-CH/t-CCUS; 80%, 66.5%, 76.5%, and 19%; P ≤ .001) and had a shorter time interval to detection from last genotoxic exposure (6.2, 5.9, 11.25, and 24.5 months; P ≤ .001) compared with PPM1Dmt/TP53wt, TP53mt/PPM1Dwt, and TP53wt/PPM1Dwt genotypes, respectively. Acknowledging the short follow-up duration, rates of malignant transformation were lower in the PPM1Dmt/TP53wt (2%) and PPM1Dmt/TP53mt (4%) groups compared with PPM1Dwt/TP53wt (12%) and PPM1Dwt/TP53mt (17%) groups (P ≤ .001), respectively. In summary, PPM1D mutations are frequently observed in t-CH/t-CCUS, with low median VAFs, and are associated with low rates of progression, even when comutated with TP53.
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)
Sater, Sam, Bifulco, Carlo B, Rodriguez-Canales, Jaime, Yeong, Joe, Akturk, Guray, Angelo, Michael, Ballesteros-Merino, Carmen, Bankhead, Peter, Basu, Subham, Blando, Jorge M, Brajkovic, Saska, Cassano, Marco, Chen, Benjamin J , Coskun, Ahmet F, Cottrell, Tricia R, Andrea, Carlos E De, Edwards, Robin H, Engle, Logan L , Fan, Rong , Feldman, Michael, Fox, Bernard A. , Galon, Jerome, Gartrell, Robyn, Gnjatic, Sacha, Green, Benjamin F, Hellebust, Anne, Hewitt, Stephen, Hollmann, Travis J, Horn, Lucas A , Howat, William J, Hoyt, Clifford C, Jensen, Shawn M, Kulasinghe, Arutha, Lassoued, Wiem , Lott, Steven, Mansfield, James, Marwitz, Sebastian , Netto, George, Page, David B. , Parra, Edwin, Rodig, Scott J, Salgado, Roberto, Schapiro, Denis, Schalper, Kurt A , Sunshine, Joel C , Surace, Michael J, Szalay, Alexander S, Thurin, Magdalena, Villasboas, Jose C, Wharton, Keith, Wistuba, Ignacio I, Yearley, Jennifer H, Yuan, Yinyin, Zaki, Geroge, Ziai, James, Gnjatic, Sacha , Netto, George J. , Egelston, Colt , Engle, Logan L , Ernstoff, Marc S. , Fan, Rong , Fox, Bernard A , Gulley, James L , Horn, Lucas A , Lassoued, Wiem , Marwitz, Sebastian , Page, David B , Rimm, David , Schalper, Kurt A , Sunshine, Joel C , Taube, Janis M , Gnjatic, Sacha , Sater, Sam, Bifulco, Carlo B, Rodriguez-Canales, Jaime, Yeong, Joe Poh-Sheng , Akturk, Guray, Angelo, Michael, Ballesteros-Merino, Carmen, Bankhead, Peter, Basu, Subham, Blando, Jorge M, Brajkovic, Saška, Cassano, Marco , Chen, Benjamin J , Coskun, Ahmet F, Cottrell, Tricia R, Andrea, Carlos E De, Edwards, Robin H, Feldman, Michael, Galon, Jérôme , Gartrell, Robyn, Green, Benjamin F, Hellebust, Anne, Hewitt, Stephen, Hollmann, Travis J, Howat, William J, Hoyt, Clifford C, Jensen, Shawn M, Kulasinghe, Arutha, Lott, Steven, Mansfield, James, Parra, Edwin, Rodig, Scott J, Salgado, Roberto, Schapiro, Denis , Surace, Michael J, Szalay, Alexander S. , Thurin, Magdalena, Villasboas, Jose C, Wharton, Keith, Wistuba, Ignacio I. , Yearley, Jennifer H, Yuan, Yinyin, Zaki, Geroge, Ziai, James

Mayo Clinic

Journal for ImmunoTherapy of Cancer | December 21, 2025 | Volume: 13 | Issue: 12 | Pages: e012280

10.1136/jitc-2025-012280 | PMID 41423269 Get It

Multiplex immunofluorescence and immunohistochemistry (mIF/IHC) are increasingly employed antibody-based technologies that use tissue sparingly and facilitate the detection of co-localized or neighboring biomarkers. Specifically, these platforms enable spatial analyses of the tumor microenvironment as well as extended applications, for example, describing normal tissue anatomy, autoimmunity, infectious diseases, etc. mIF/IHC has greatly enhanced biomarker discovery efforts, and a growing number of studies suggest superiority to traditional IHC. Standardization of staining approaches, reporting of image analysis strategies and resultant data is critical for facilitating cross-study comparisons, validation, deployment, and generalization of findings. To address this challenge, The Society for Immunotherapy of Cancer (SITC) previously published two articles providing best practice guidelines for mIF/IHC staining, image analysis, and data sharing. Here, SITC convened stakeholders to develop the third article in the series, a consensus checklist for scientific reporting of mIF/IHC data to support and complement the best practice guidelines. The checklist includes critical components of mIF/IHC applications to be defined within publications such as detailed descriptions of analytical validation; image acquisition, selection, and registration methods; and cell clustering and spatial analysis strategies, amongst others. Such information will help with data reproducibility and comparison across studies towards future drug and assay development.